Combination of interferon α with mannan peptide in treatment of HBeAg-positive chronic hepatitis B
10.3760/cma.j.issn.1674-3397.2009.05.004
- VernacularTitle:干扰素α联合甘露聚糖肽治疗HBeAg阳性慢性乙型肝炎临床探讨
- Author:
Xiao LING
;
Zhenxiang TANG
;
Shuquan CHENG
;
Yongchao XIAN
;
Xin YE
;
Yifeng CAI
;
Chengjun HUANG
;
Hui NI
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B;
Hepatitis B e antigen;
Combined therapy;
Mannan peptide;
Interferon α
- From:
Chinese Journal of Clinical Infectious Diseases
2009;2(5):268-272
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect of IFNα combined with mannan peptide in treatment of patients with HBeAg-positive chronic hepatitis B ( CHB ). Methods Eighty HBeAg-positive CHB patients with HBV DNA quantity ranging from 10 to 10 eopies/mL were enrolled and randomized into the treatment group and the control group ( n = 40 for each ). Patients in treatment group were given daily subcutaneous injection of IFNα-2b 5,000,000 U for 52 weeks, and received mannan peptide 10 mg per intravenous injection or 2. 5 mg per intramuscular injection for a total of 2 to 3 treatment courses (12 weeks for each). The control group received only IFNα-2b treatment. Liver function, serum markers of hepatitis B, HBV DNA quantity and blood tests were performed before the treatment and at 2, 4, 8, 16, 26 and 52-week during the treatment; and the adverse effects were recorded. Results The rates for ALT normalization, negative HBsAg, negative HBeAg, HBeAg seroconversion and negative HBV DNA were 91. 8% , 17. 5% , 52. 5% , 27. 5 % and 47. 5% at 52nd week in the treatment group, while those in the control group were 80. 0% , 12. 5% , 30. 0% , 10. 0 % and 25. 0% , respectively. There were significant differences in HBeAg-negative, HBeAg-seroeonversion and HBV DNA-negative rates between two groups (χ2 = 4. 178, 4.021 and 4.381, P < 0. 05 ) , and these indexes in the treatment group were increased to 57. 5% , 30. 0% and 50. 0 respectively at 52nd week after drug withdraw. White blood cells began to be elevated at 4th week and were restored to the normal levels at 8th week in the treatment group, while the count in the control was lower than the normal value even at 52nd week of the treatment with the average of (3.45±1. 18)×109/L. Conclusion Alpha-interferon combined with mannan peptide therapy is effective for patients with HBeAg-positive CHB, which may restore the declined peripheral WBC counts induced by interferon and improve the compliance.
